Opthea AAQS 2024

Šta radi Opthea?

Opthea Ltd is a biopharmaceutical company specializing in the development of novel therapies for various eye diseases. The company was founded in 1985 in Melbourne, Australia as a spin-off from the Burnet Institute for Medical Research and Public Health. Since then, Opthea has become a leading company in ophthalmology and is researching innovative therapies that have the potential to improve the lives of millions of patients worldwide. Opthea's business model is to develop novel therapies for various eye diseases and market these therapies through partnerships with established pharmaceutical companies. The company focuses on developing therapies based on the inhibition of growth factors and other signaling pathways that promote the development of abnormal blood vessels and inflammation. This therapeutic principle offers a promising way to effectively treat various eye diseases. Opthea specializes in developing therapies for the treatment of wet age-related macular degeneration (AMD), which is the leading cause of severe visual impairment in older people. Opthea is developing a therapy aimed at inhibiting the excessive formation of blood vessels in the macula of the eye, which can impair vision. The drug called OPT-302 is used in combination therapies with existing treatments for wet AMD and has the potential to slow down the progression of the disease and improve vision. In addition to the therapy for wet AMD, Opthea is also researching therapy options for other eye diseases such as diabetic retinopathy, retinal vein occlusion, and corneal diseases. Opthea has filed numerous patents in this field and collaborates with various academic and clinical partners to advance the development of innovative therapies. Another important component of Opthea's business model is collaboration with established pharmaceutical companies. In 2020, Opthea entered into a licensing agreement with the pharmaceutical company Novartis, which includes exclusive distribution and marketing rights for the drug OPT-302 in Europe, Japan, and other countries outside of North America. This partnership allows Opthea to benefit from collaboration with an experienced and established partner while maximizing the potential of its innovative therapy. In summary, Opthea is a promising company in ophthalmology that specializes in the development of innovative therapies for various eye diseases. The company works closely with academic and clinical partners and leverages the advantages of partnerships with established pharmaceutical companies to maximize the potential of its therapies. With the therapy for wet AMD already in the pipeline, Opthea is expected to develop further therapy options in the future that will contribute to improving the lives of millions of patients worldwide. Opthea ist eines der beliebtesten Unternehmen auf Eulerpool.com.